Last updated: 2026-09-16 11:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Annexon, Inc. (ANNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,92, with a market capitalisation of $748,84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,49 to $7,18. This page covers its latest market performance, valuation, price trends and company information.
$748,84M | |
$3,92 | |
$38,01 | |
$1,29 | |
$3,92 | |
2,20K | |
3,58M | |
-- | |
$7,18 | |
$2,49 | |
-- | |
-- |
Annexon, Inc. (ANNX) is trading at $3,92 in pre-market trading as of 2026-09-16 10:16:00, unchanged from the previous close of $3,92
Pre-market trading shows how investors are pricing ANNX before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Annexon, Inc. (ANNX) moved from $4,87 to $3,92, representing a decline of 19,51% ($0,95).
The stock traded between $3,79 and $4,91 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3,27 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30,5%
ANNX is currently trading at $3,92, placing it 30,5% of the way from its 52-week low of $2,49 to its 52-week high of $7,18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Annexon, Inc. (ANNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.